6 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 1 | Terminated 1 |
Follow Malignant Solid Neoplasm: new trials by email Literature Review of Malignant Solid Neoplasm trials Research Report on Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-11-17 |
| Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy Xisomab 3G3 - Lymphoma, Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 9 | 2021-02-25 | 2024-01-24 |
| Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis Infliximab, Intravenous Immunoglobulin Therapy, Prednisone - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 1 | 2021-01-07 | 2026-09-29 |
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Tocilizumab for Patients With Cancer and COVID-19 Disease Tocilizumab - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2020-05-28 | 2025-02-04 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine - Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2018-10-16 | 2025-04-17 |
Hematologic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1) · Pneumonia (1) · Respiratory Distress Syndrome (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (6) · Neoplasms by Site (5) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Lung Diseases (2) · Neoplasms by Histologic Type (2) · Respiratory Tract Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adnexal Diseases (1) · Blood Protein Disorders (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
Disulfides (2) · Immunoglobulin G (2) · tocilizumab (2) · 4-toluenesulfonyl fluoride (1) · AB023 (1) · CTLA-4 Antigen (1) · Cyclophosphamide (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Infliximab (1) · Interferon alpha-2 (1) · Interleukin-2 (1) · Introns (1) · Ipilimumab (1) · Methylprednisolone (1)
M.D. Anderson Cancer Center (2) · ECOG-ACRIN Cancer Research Group (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1)
United States (6)
Amir A Jazaeri (1) · Igor Puzanov (1) · Jarushka Naidoo (1) · Joseph Shatzel, M.D. (1) · Richard F Little (1) · Rodabe Amaria, MD (1)
PMID 31401903, PMID 33568350, PMID 35537412, PMID 37328287, PMID 37970718, PMID 38309721
P30CA016056 (1), R01HL151367 (1), UG1CA189828 (1)